Related Experiment Video
Updated: May 18, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
New therapeutic approaches for malignant glioma: in search of the Rosetta stone
Brenda Auffinger1, Bart Thaci, Pragati Nigam
1The Brain Tumor Center, The University of Chicago Pritzker School of Medicine 5841 South Maryland Ave, M/C 3026, Chicago, IL 60637.
Abstract:
Malignant gliomas are heterogeneous, diffuse and highly infiltrating by nature. Despite wide surgical resection and improvements in radio- and chemotherapies, the prognosis of patients with glioblastoma multiforme remains extremely poor, with a median survival time of only 14.5 months from diagnosis to death. Particular challenges for glioblastoma multiforme therapy are posed by limitations in the extent of feasible surgical resections, distinct tumor heterogeneity, difficulties in drug delivery across the blood-brain barrier and low drug distribution within the tumor. Therefore, new paradigms permitting tumor-specific targeting and extensive intratumoral distribution must be developed to allow an efficient therapeutic delivery. This review highlights the latest advances in the treatment of glioblastoma multiforme and the recent developments that have resulted from the interchange between preclinical and clinical efforts. We also summarize and discuss novel therapies for malignant glioma, focusing on advances in the following main topics of glioblastoma multiforme therapy: immunotherapy, gene therapy, stem cell-based therapies and nanotechnology. We discuss strategies and outcomes of emerging therapeutic approaches in these fields, and the main challenges associated with the integration of discoveries that occur in the laboratory into clinical practice.
Insights
Malignant gliomas like glioblastoma multiforme have poor prognoses due to tumor infiltration and treatment challenges. Novel therapies including immunotherapy, gene therapy, and nanotechnology offer new treatment paradigms for these aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Therapy
- Biomedical Engineering
Background:
- Malignant gliomas, particularly glioblastoma multiforme, exhibit aggressive infiltration and heterogeneity.
- Current treatments (surgery, radiation, chemotherapy) yield poor patient prognoses with a median survival of 14.5 months.
- Therapeutic challenges include limited surgical resection, blood-brain barrier penetration, and intratumoral drug distribution.
Purpose of the Study:
- To review recent advances in glioblastoma multiforme (GBM) treatment.
- To discuss novel therapeutic strategies emerging from preclinical and clinical research.
- To highlight challenges in translating laboratory discoveries into clinical practice for malignant glioma therapy.
Main Methods:
- Review of current literature on glioblastoma multiforme (GBM) therapies.
- Focus on immunotherapy, gene therapy, stem cell-based therapies, and nanotechnology.
- Analysis of preclinical and clinical research interchange for emerging treatments.
Main Results:
- Significant progress in immunotherapy, gene therapy, stem cell-based treatments, and nanotechnology for malignant gliomas.
- Identification of strategies and outcomes for these novel therapeutic approaches.
- Discussion of challenges in integrating new discoveries into clinical settings.
Conclusions:
- New therapeutic paradigms are essential for effective glioblastoma multiforme (GBM) treatment.
- Advances in immunotherapy, gene therapy, stem cell therapy, and nanotechnology show promise.
- Bridging the gap between laboratory research and clinical application is crucial for improving patient outcomes.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
09:18Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
